ERBB2 and breast carcinoma: MAHNP–DOX treatment decreased the growth rate of HER2 positive breast cancer cell lines BT474 and SKBR3 in a dose–dependent manner (IC50 values 747 and 110 nM for BT474 and SKBR3 cells, respectively).